NGEN
NERVGEN PHARMA CORP.
$1.82
-2.15%
$149.6M
No data for this timeframe.
Vol
Market Cap$149.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases3
Recent Activity
Jun 4, 2026
short_volume
Short Volume: NGEN — 61.5% short (0.5M / 0.8M)
Short: 476,300 | Exempt: 4,545 | TRF Vol: 774,077 | Short Ratio: 61.5% | Off-exchange volume (dark p
Jun 1, 2026
SEC
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per
6-K — Impact 6/10
May 27, 2026
SEC
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th
EFFECT — Impact 4/10
May 26, 2026
SEC
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study, demo
6-K — Impact 7/10
May 22, 2026
Press
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa
Impact 6/10
May 21, 2026
Press
NervGen Pharma announced an underwritten public offering of common shares and warrants (including pre-funded warrants) t
Impact 5/10
Price Targets
$11.21
+519.1% upside
Strong Buy
Current $1.81
Low $5.03
Median $10.10
High $18.00
6 analysts
$5.03
$18.00
Analyst Ratings
1Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.07 ▼ -12.9% | $-0.07 — $-0.06 | 2 | |
| Next Q | $-0.07 ▼ -15.9% | $-0.07 — $-0.07 | 2 | |
| Current FY | $-0.26 ▲ +0.7% | $-0.29 — $-0.23 | 40% YoY | 2 |
| Next FY | $-0.38 ▼ -41.1% | $-0.49 — $-0.27 | -45% YoY | 2 |
Latest Reports
BEARISH
6-K
6/10
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per
Jun 1, 2026
NEUTRAL
EFFECT
4/10
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th
May 27, 2026
BEARISH
Press
6/10
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa
May 22, 2026
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 2 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.3/10.
BEARISH
6-K
6/10
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying w
Jun 1, 2026
NEUTRAL
EFFECT
4/10
The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on Ma
May 27, 2026
BULLISH
6-K
7/10
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CON
May 26, 2026
BEARISH
6-K
7/10
NervGen Pharma announced a $60.0 million underwritten public offering of 24 million common shares an
May 22, 2026
BULLISH
6-K
5/10
NervGen reported Q1 2026 results with a net loss of $1.7M, improved from $3.9M a year ago due to non
May 18, 2026
BEARISH
PRESS-RELEASE
6/10
NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% m
May 18, 2026
NEUTRAL
6-K
2/10
NervGen Pharma filed a management proxy circular for its April 23, 2026 annual general meeting, seek
Apr 27, 2026
BEARISH
6/10
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with sh
May 22, 2026
BEARISH
5/10
NervGen Pharma announced an underwritten public offering of common shares and warrants (including pr
May 21, 2026
MIXED
6/10
NervGen Pharma reported full-year 2025 financial results and provided clinical updates, including co
Mar 31, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 1 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.21 mean target
+519.1% upside
Strong Buy (3.00)
$5.03 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $1.81 |
| Target Low | $5.03 |
| Target Mean | $11.21 |
| Target Median | $10.10 |
| Target High | $18.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.07 | $-0.07 | $-0.06 | — | -12.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.07 | $-0.07 | $-0.07 | — | -15.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.26 | $-0.29 | $-0.23 | 40.2% | +0.7% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.38 | $-0.49 | $-0.27 | -45.1% | -41.1% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.066 | |
| 7d ago | $-0.066 | +0.000 |
| 30d ago | $-0.058 | -0.007 |
| 60d ago | $0.000 | -0.066 |
| 90d ago | $0.000 | -0.066 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 1 | 6 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
WHAT ARE THE BIGGEST LOSERS TODAY AND WHY
▲ 1
💬 1
⚡ 0.5
Public offering of stock: NervGen Pharmaceuticals: $ngen and what should current holders do about it?
▲ 1
💬 0
⚡ 0.5
Nervgen Pharma: $NGEN
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
short_volume
Short Volume: NGEN — 61.5% short (0.5M / 0.8M)
Short: 476,300 | Exempt: 4,545 | TRF Vol: 774,077 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 29, 2026
Clinical Trial
NVG-291 in Spinal Cord Injury Subjects
Phase Phase 2 — TERMINATED
May 29, 2026
short_volume
Short Volume: NGEN — 73.0% short (0.4M / 0.6M)
Short: 428,773 | Exempt: 0 | TRF Vol: 587,695 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: NGEN — 60.0% short (0.4M / 0.7M)
Short: 402,895 | Exempt: 1,559 | TRF Vol: 671,528 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: NGEN — 67.6% short (0.6M / 0.8M)
Short: 569,267 | Exempt: 0 | TRF Vol: 842,559 | Short Ratio: 67.6% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
<p>VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 26, 2026
short_volume
Short Volume: NGEN — 73.2% short (2.1M / 2.9M)
Short: 2,114,969 | Exempt: 122,049 | TRF Vol: 2,888,570 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
May 22, 2026
offering
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
<p>VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 22, 2026
short_volume
Short Volume: NGEN — 60.2% short (4.2M / 7.0M)
Short: 4,217,437 | Exempt: 312,682 | TRF Vol: 7,005,755 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
offering
NervGen Announces Proposed Public Offering of Securities
<p>VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
May 18, 2026
earnings
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
<p>VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage
Apr 27, 2026
other
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
<p align="left">VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a
Apr 13, 2026
other
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
<p>VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Apr 7, 2026
fda
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
<p>VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Mar 31, 2026
earnings
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
<p>VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stag
Mar 12, 2026
delisting
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
<p>VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a